By Kaley Day
Affordable housing in Denver—a seemingly contradictory statement and an issue that, at the very least, causes headaches for those trying to navigate it, and at worst leads to homelessness and displacement for our most vulnerable community members. Denver’s housing market is among the fastest growing in the country, and that growth leaves behind thousands of people with intellectual and developmental disabilities (I/DD) who are unable to keep up with rising costs and lack of inclusivity and accessibility.
[Read more…] about Inclusive Housing Report Highlights Need for Creative Action in DenverLegislative Wins and a Brighter Future
By Kaley Day and the Arc of Colorado
The 2021 Colorado legislative session began with uncertainty. Amid COVID protocols that required distancing and virtual testimony, economic concerns, and fear that any bill with a fiscal note may not make it to the governor’s desk, advocates and community members were unsure how far their efforts to promote legislation for the disability community would go. In the end there was cause for celebration as the session closed officially on June 8th and the state saw major legislation, some years and decades in the making, passed in order to support and advance the rights of Coloradoans with disabilities.
[Read more…] about Legislative Wins and a Brighter FuturePriorities: The COVID-19 Vaccine
An Interview With Kaley Day
Nearly one year after COVID-19 changed our world and impacted lives globally, the release of two FDA-approved vaccines has offered hope to many. For Colorado’s intellectual and developmental disability community, the relief offered by the vaccine has become imperative to a population more impacted by social isolation, where the function of essential services and supports has changed, and many live with co-occurring or underlying conditions. In these interviews, AdvocacyDenver seeks to understand the development of Colorado’s vaccine priority schedule, along with the perspective of advocates and family members.
[Read more…] about Priorities: The COVID-19 Vaccine